Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.

In this animal study, researchers found that finasteride reduced bacterial infection and inflammation in chronic bacterial prostatitis, with the greatest effect when combined with ciprofloxacin.

High-dose corticosteroids can significantly regrow hair in severe alopecia areata.

Active vitamin D3 might protect hair follicles from radiation damage.

In this systematic review, oral minoxidil was found to be a safe and effective treatment for androgenetic alopecia and alopecia areata, with additional benefits for female pattern hair loss and other types of alopecia, although common side effects included hypertrichosis and postural hypotension.

This pilot study found that among male androgenetic alopecia patients, 2.5 mg oral minoxidil with platelet-rich plasma led to higher patient satisfaction than 1.25 mg, though hair count improvements were not statistically significant.

This study found that low-dose oral minoxidil (≤5 mg/day) effectively increased hair number and diameter in men and women with androgenetic alopecia, and was generally well-tolerated with mostly mild adverse effects, although serious complications were rare and associated mainly with pre-existing heart conditions.

This study concluded that while methotrexate-related adverse events were infrequent in early rheumatoid arthritis patients taking adalimumab, some increased with higher methotrexate doses, suggesting use of the lowest effective dose.

In this study, low-dose oral minoxidil for hair loss was associated with infrequent systemic adverse effects, and only 1.7% of patients discontinued treatment due to these effects.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This document studied minoxidil in healthy volunteers. Minoxidil is quickly absorbed and eliminated from the body.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study found that a low-dose intermittent finasteride regimen significantly reduced hirsutism scores in adolescent girls with PCOS or idiopathic hirsutism, with similar efficacy but potentially safer and less expensive than continuous administration.

This review discusses recent advancements and new approvals in the medical treatment of lower urinary tract symptoms, particularly highlighting drugs for nocturia and ongoing trials for multiple related conditions, while reporting no new clinical results.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

This study found that isolated red light may serve as an alternative for photo-immunotherapy without additional photosensitizers, as it did not reduce keratinocyte differentiation markers or increase photo-oxidative damage, unlike treatment with IL-4 or UVA1/blue light.

This study observed eyebrow regrowth in 7 patients with frontal fibrosing alopecia treated with low-dose oral minoxidil, suggesting it may be a promising treatment option, especially in early disease stages.

This article describes the characteristics and management of hypertrichosis induced by low-dose oral minoxidil used for hair disorders, but reports no new clinical findings.

This study reported that a subcutaneous injection formulation using PLGA microspheres to release finasteride stably achieved sustained monthly drug delivery without burst release in beagle dogs, with a dose of 16.8 mg identified as optimal for potential first-in-human trials.

This review summarizes the anatomy and physiology of the arrector pili muscle and discusses its potential role in hair loss disorders, reporting no new clinical results.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

This study found that the ALK5 inhibitor TP0427736 inhibited TGF-β signaling in cell and mouse models, suggesting potential as a new treatment for androgenic alopecia.

This study found that human hair follicles demonstrated a dose-dependent response to light in an ex vivo photoepilation model, which could predict the clinical efficacy and permanency of light-based hair removal devices.

Finasteride daily doesn't affect sperm production or semen in young men.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This study highlights the complex clinical issues associated with using low dose oral minoxidil for alopecia, emphasizing the need for careful cardiology-dermatology collaboration due to rare but serious cardiovascular risks, especially in patients with existing cardiorenal or cardiovascular concerns.

This randomized, placebo-controlled trial reported that USPlus PRO saw palmetto extract significantly improved lower urinary tract symptoms, including voiding, incomplete emptying, and weak stream, as well as sexual function in males over 12 weeks, while maintaining a favorable safety profile.

This study suggests that side effects of low-dose oral minoxidil for hair loss are infrequent and demographics did not influence this risk, but dosage relative to body weight may affect adverse event incidence.

This article evaluated evidence on finasteride's effects on male reproductive health, finding contradictory data about its adverse effects, but consensus that such cases are infrequent in research and clinical settings.

This study found no significant association between the degree of male-pattern baldness and serum 25-hydroxyvitamin D levels in healthy middle-aged and older men.